Submit RFP

On January 5th, 2026, on the occasion of the visit of Irish Prime Minister Mr. Micheál Martin to China, ICON China team attended a business dinner hosted by the Irish government in Beijing. The event was held at the join...

Missed our recent webinar from Symphony Health, an ICON plc company? The recording for Riding the data wave: How pharma can navigate disruptions in open claims is now available. Discover how life sciences organisatio...

Learn the pros and cons of different AI models for SaMDs. The right model and data training sets are essential to develop your AI-enabled device. Our latest whitepaper lays out the best practices for data and AI models...

What should you consider when choosing a training dataset for your AI-enabled SaMD? Our whitepaper has the answers. Learn about AI models and data best practices and plan for your FDA Pre-Sub. Download it today. https://...

With over 10,000 journals and conferences to consider it’s an important question to answer. There are 50+ accessible points of metadata to use in focusing your selection for a publishing source. Schedule a demo to learn ...

Long-term follow-up for vaccines may seem to be a distant concern when clinical trials are just beginning, but it can be critical to have a plan for follow-up at the outset. Learn considerations for follow-up design, s...

Potent and long-lasting incretin receptor agonists like GLP-1 RAs target the molecular mechanisms underlying glucose metabolism. Learn why these therapies are ushering in a new era of multi-indication drug development in...

Deepali Suri shares her vision for the biotech sector in 2026 and beyond. With over two decades of experience across pharma, biotech, and CROs, she outlines a clear strategy to strengthen innovation, streamline develop...

Therapeutic developers can aid control of the HIV epidemic by creating simpler, longer-acting prevention methods that perform better in real-world settings. ICON's whitepaper details these advances and best practices for...

Demographic Matching in Organ Impairment Studies: Why It Matters Organ impairment (OI) studies are critical for safe and effective drug development—but did you know that demographic matching can make or break the accurac...

In 2025 ICON was recognised in global rankings by both TIME and Fortune magazines celebrating organisations excelling in financial stability and environmental sustainability. Learn more. https://ow.ly/aqkw50XSPP5

Continuing our series of articles discussing managing risk for medical devices, ICON’s regulatory expert Jeremy Tinkler turns his focus on the biological risk estimate and looks into the logical basis for the use of comp...